Recently Expired Drugs

1. List of Actonel drug patents

ACTONEL's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7192938 APIL Method of treatment using bisphosphonic acid
May, 2023

(23 days ago)

US7718634 APIL Method of treatment using bisphosphonic acid
May, 2023

(23 days ago)

Do you want to check out ACTONEL patents from before 2022?

Drugs and Companies using RISEDRONATE SODIUM ingredient

Market Authorisation Date: 27 March, 1998

Treatment: Prevention and treatment of osteoporosis; Treatment of osteoporosis in postmenopausal women

Dosage: TABLET;ORAL

How can I launch a generic of ACTONEL before it's patent expiration?
More Information on Dosage

ACTONEL family patents

7

Korea, Republic of

6

European Union

5

United States

5

Japan

3

Australia

2

Spain

2

Malaysia

2

Denmark

2

Poland

2

China

2

Russia

2

Canada

2

Argentina

2

Norway

2

New Zealand

2

Cyprus

2

Israel

2

Portugal

2

Slovenia

1

Uruguay

1

Panama

1

Austria

1

Hong Kong

1

Germany

1

Brazil

1

Croatia

1

Guatemala

1

Peru

1

Taiwan

1

Mexico

1

Ecuador

1

South Africa

2. List of Addyi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8227471 SPROUT PHARMS Treating sexual desire disorders with flibanserin
May, 2023

(20 days ago)

Do you want to check out ADDYI patents from before 2022?

Drugs and Companies using FLIBANSERIN ingredient

Market Authorisation Date: 18 August, 2015

Treatment: Use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd)

Dosage: TABLET;ORAL

More Information on Dosage

ADDYI family patents

13

United States

4

China

4

European Union

3

Japan

3

Korea, Republic of

2

Argentina

1

Spain

1

Austria

1

Malaysia

1

Denmark

1

Germany

1

Poland

YU

1

Yugoslavia

1

Brazil

1

Canada

1

Ukraine

EA

1

EA

1

Norway

1

ME

1

New Zealand

1

Croatia

1

Israel

1

Portugal

1

Mexico

1

Australia

1

Ecuador

1

South Africa

1

Slovenia

1

Hungary

3. List of Aggrastat drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6770660 MEDICURE Method for inhibiting platelet aggregation
May, 2023

(28 days ago)

Do you want to check out AGGRASTAT patents from before 2022?

Drugs and Companies using TIROFIBAN HYDROCHLORIDE ingredient

Market Authorisation Date: 14 May, 1998

Treatment: A dosing regimen of aggrastat (tirofiban hydrochloride)(25mcg/kg followed by 0.15mcg/kg/min infusion) to reduce the rate of thrombotic coronary events associated with acute coronary syndrome (acs) in ...

Dosage: INJECTABLE;INJECTION; SOLUTION;INJECTION

How can I launch a generic of AGGRASTAT before it's patent expiration?
More Information on Dosage

AGGRASTAT family patents

8

United States

1

Canada

1

Japan

1

Australia

1

European Union

4. List of Airduo Digihaler drug patents

AIRDUO DIGIHALER's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7540282 TEVA PHARM Reservoir pressure system for medicament inhaler
May, 2023

(23 days ago)

Do you want to check out AIRDUO DIGIHALER patents from before 2022?
Exclusivity Exclusivity Expiration
M (M) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

AIRDUO DIGIHALER family patents

16

United States

6

Spain

6

Australia

6

European Union

5

Uruguay

5

Korea, Republic of

5

United Kingdom

5

Peru

5

Canada

5

Portugal

5

Taiwan

5

Japan

5

Denmark

4

Austria

3

Germany

3

Cyprus

3

Argentina

1

Slovenia

5. List of Amturnide drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8183295 NOVARTIS Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
May, 2023

(13 days ago)

Do you want to check out AMTURNIDE patents from before 2022?

Drugs and Companies using ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE ingredient

Market Authorisation Date: 21 December, 2010

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

AMTURNIDE family patents

4

United States

3

Korea, Republic of

3

European Union

2

Japan

1

Spain

1

Austria

1

Hong Kong

1

Denmark

1

Poland

1

China

1

Russia

1

Brazil

1

Canada

1

Norway

1

New Zealand

1

Cyprus

1

Israel

1

Portugal

1

Mexico

1

Australia

1

Ecuador

1

South Africa

1

Luxembourg

1

Slovenia

6. List of Armonair Digihaler drug patents

ARMONAIR DIGIHALER's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7540282 TEVA PHARM Reservoir pressure system for medicament inhaler
May, 2023

(23 days ago)

Do you want to check out ARMONAIR DIGIHALER patents from before 2022?
Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 9, 2024
New Strength (NS) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARMONAIR DIGIHALER family patents

16

United States

6

Spain

6

Australia

6

European Union

5

Uruguay

5

Korea, Republic of

5

United Kingdom

5

Peru

5

Canada

5

Portugal

5

Taiwan

5

Japan

5

Denmark

4

Austria

3

Germany

3

Cyprus

3

Argentina

1

Slovenia

7. List of Banzel drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6740669

(Pediatric)

EISAI INC Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic
May, 2023

(15 days ago)

Do you want to check out BANZEL patents from before 2022?

Drugs and Companies using RUFINAMIDE ingredient

Market Authorisation Date: 14 November, 2008

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of BANZEL before it's patent expiration?
More Information on Dosage

8. List of Boniva drug patents

BONIVA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7192938 HOFFMANN LA ROCHE Method of treatment using bisphosphonic acid
May, 2023

(23 days ago)

US7718634 HOFFMANN LA ROCHE Method of treatment using bisphosphonic acid
May, 2023

(23 days ago)

US7410957 HOFFMANN LA ROCHE Method of treatment using bisphosphonic acid
May, 2023

(23 days ago)

Do you want to check out BONIVA patents from before 2022?

Drugs and Companies using IBANDRONATE SODIUM ingredient

Market Authorisation Date: 16 May, 2003

Treatment: Treatment and prevention of osteoporosis in postmenopausal women by once-monthly oral administration of ibandronate sodium monohydrate equivalent to 150mg of ibandronic acid; Treatment and prevention ...

Dosage: TABLET;ORAL

How can I launch a generic of BONIVA before it's patent expiration?
More Information on Dosage

BONIVA family patents

7

Korea, Republic of

6

European Union

5

United States

5

Japan

3

Australia

2

Spain

2

Malaysia

2

Denmark

2

Poland

2

China

2

Russia

2

Canada

2

Argentina

2

Norway

2

New Zealand

2

Cyprus

2

Israel

2

Portugal

2

Slovenia

1

Uruguay

1

Panama

1

Austria

1

Hong Kong

1

Germany

1

Brazil

1

Croatia

1

Guatemala

1

Peru

1

Taiwan

1

Mexico

1

Ecuador

1

South Africa

9. List of Chlorhexidine Gluconate drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7595021 SAGE PRODS Method of providing alcohol-free disinfection
May, 2023

(17 days ago)

Do you want to check out CHLORHEXIDINE GLUCONATE patents from before 2022?

Drugs and Companies using CHLORHEXIDINE GLUCONATE ingredient

Market Authorisation Date: 25 April, 2005

Treatment: For the preparation of skin prior to surgery; Helps reduce bacteria that can potentially cause skin infection

Dosage: CLOTH;TOPICAL

More Information on Dosage

CHLORHEXIDINE GLUCONATE family patents

7

United States

2

Canada

10. List of Exforge Hct drug patents

EXFORGE HCT's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101599 NOVARTIS Pharmaceutical composition containing anti-hypertensive agents
May, 2023

(13 days ago)

US8475839 NOVARTIS Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
May, 2023

(13 days ago)

Do you want to check out EXFORGE HCT patents from before 2022?

Drugs and Companies using AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN ingredient

Market Authorisation Date: 30 April, 2009

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of EXFORGE HCT before it's patent expiration?
More Information on Dosage

EXFORGE HCT family patents

8

United States

4

China

3

Japan

3

Korea, Republic of

3

Peru

3

European Union

2

Hong Kong

2

Russia

2

Brazil

2

Canada

2

Argentina

2

Norway

2

New Zealand

2

Taiwan

2

Mexico

2

Australia

2

Ecuador

2

South Africa

1

Spain

1

Austria

1

Malaysia

1

Denmark

1

Poland

1

Germany

1

Morocco

1

Cyprus

1

Chile

1

Israel

1

Portugal

1

Egypt

1

Tunisia

1

Slovenia

11. List of Mydayis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6913768 TAKEDA PHARMS USA Sustained release delivery of amphetamine salts
May, 2023

(5 days ago)

Do you want to check out MYDAYIS patents from before 2022?
Exclusivity Exclusivity Expiration
Pediatric Exclusivity (PED) Mar 13, 2023

Drugs and Companies using AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE ingredient

Market Authorisation Date: 20 June, 2017

Treatment: Treatment of attention deficit hyperactivity disorder

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of MYDAYIS before it's patent expiration?
More Information on Dosage

MYDAYIS family patents

4

United States

1

Spain

1

Austria

1

Hong Kong

1

Iceland

1

Denmark

AP

1

AP

1

Germany

1

Poland

1

China

1

Brazil

1

Canada

1

Ukraine

1

Morocco

EA

1

EA

1

Norway

1

Japan

OA

1

OA

1

New Zealand

1

Croatia

1

Korea, Republic of

1

Cyprus

1

Israel

1

Mexico

1

Australia

1

Costa Rica

1

Ecuador

1

South Africa

1

Slovenia

1

European Union

12. List of Naropin drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8118802 FRESENIUS KABI USA Connector for packaging containing medical fluids and packaging for medical fluids
May, 2023

(11 days ago)

Do you want to check out NAROPIN patents from before 2022?

Drugs and Companies using ROPIVACAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 September, 1996

Treatment: NA

Dosage: SOLUTION;INJECTION

How can I launch a generic of NAROPIN before it's patent expiration?
More Information on Dosage

NAROPIN family patents

4

European Union

2

United States

2

Germany

1

Spain

1

Hong Kong

1

Austria

1

India

1

Denmark

1

Poland

1

China

1

Brazil

1

Canada

1

Norway

1

Japan

1

Korea, Republic of

1

Portugal

1

Mexico

1

Australia

1

South Africa

1

Slovenia

13. List of Nocdurna drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9220747 FERRING PHARMS INC Methods using desmopressin acetate in orodispersible form
May, 2023

(22 days ago)

US9504647 FERRING PHARMS INC Pharmaceutical formulations of desmopressin
May, 2023

(22 days ago)

US9919025 FERRING PHARMS INC Pharmaceutical formulations of desmopressin
May, 2023

(22 days ago)

US10307459 FERRING PHARMS INC Pharmaceutical formulations of desmopressin
May, 2023

(22 days ago)

Do you want to check out NOCDURNA patents from before 2022?

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Market Authorisation Date: 21 June, 2018

Treatment: Treatment of nocturia due to nocturnal polyuria in adults

Dosage: TABLET;SUBLINGUAL

More Information on Dosage

NOCDURNA family patents

15

United States

3

Argentina

3

Australia

2

Uruguay

IB

2

IB

2

Germany

2

China

1

Spain

1

Austria

1

Hong Kong

1

Malaysia

1

Denmark

1

Poland

1

United Kingdom

1

Russia

1

Brazil

1

Canada

1

Ukraine

1

Norway

1

Japan

1

New Zealand

1

Croatia

1

Korea, Republic of

1

Israel

1

Portugal

1

Taiwan

1

Mexico

1

South Africa

1

Slovenia

1

European Union

14. List of Noctiva drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7579321 SERENITY PHARMS LLC Pharmaceutical compositions including low dosages of desmopressin
May, 2023

(23 days ago)

US7405203 SERENITY PHARMS LLC Pharmaceutical compositions including low dosages of desmopressin
May, 2023

(23 days ago)

Do you want to check out NOCTIVA patents from before 2022?

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Market Authorisation Date: 03 March, 2017

Treatment: A method of treating nocturia due to nocturnal polyuria in adults

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

NOCTIVA family patents

15

United States

3

Argentina

3

Australia

2

Uruguay

IB

2

IB

2

Germany

2

China

1

Spain

1

Austria

1

Hong Kong

1

Malaysia

1

Denmark

1

Poland

1

United Kingdom

1

Russia

1

Brazil

1

Canada

1

Ukraine

1

Norway

1

Japan

1

New Zealand

1

Croatia

1

Korea, Republic of

1

Israel

1

Portugal

1

Taiwan

1

Mexico

1

South Africa

1

Slovenia

1

European Union

15. List of Pomalyst drug patents

POMALYST's oppositions filed in EPO
Can you believe POMALYST received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8673939 CELGENE Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
May, 2023

(14 days ago)

US8735428 CELGENE Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
May, 2023

(14 days ago)

Do you want to check out POMALYST patents from before 2022?
Exclusivity Exclusivity Expiration
M (M) Nov 20, 2023
Orphan Drug Exclusivity (ODE) May 14, 2027
Pediatric Exclusivity (PED) May 20, 2024

Drugs and Companies using POMALIDOMIDE ingredient

Market Authorisation Date: 08 February, 2013

Treatment: Use of pomalidomide for the treatment of multiple myeloma; Use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a pro...

Dosage: CAPSULE;ORAL

How can I launch a generic of POMALYST before it's patent expiration?
More Information on Dosage

POMALYST family patents

89

United States

27

Canada

26

China

24

European Union

23

Japan

13

New Zealand

13

Korea, Republic of

13

Australia

11

Mexico

9

Hong Kong

8

Israel

7

Spain

7

Denmark

7

Portugal

7

South Africa

6

Norway

6

Taiwan

5

Poland

5

Brazil

4

Cyprus

4

Costa Rica

4

Slovenia

3

Russia

3

Ukraine

3

Argentina

3

ME

3

Hungary

2

Austria

2

Iceland

2

RS

2

Peru

2

Ecuador

AP

1

AP

1

Germany

YU

1

Yugoslavia

1

Morocco

EA

1

EA

OA

1

OA

1

Croatia

1

Georgia

1

Luxembourg

16. List of Proair Digihaler drug patents

PROAIR DIGIHALER's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7540282 TEVA BRANDED PHARM Reservoir pressure system for medicament inhaler
May, 2023

(23 days ago)

Do you want to check out PROAIR DIGIHALER patents from before 2022?

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 31 March, 2015

Treatment: NA

Dosage: POWDER, METERED;INHALATION

More Information on Dosage

PROAIR DIGIHALER family patents

16

United States

6

Spain

6

Australia

6

European Union

5

Uruguay

5

Korea, Republic of

5

United Kingdom

5

Peru

5

Canada

5

Portugal

5

Taiwan

5

Japan

5

Denmark

4

Austria

3

Germany

3

Cyprus

3

Argentina

1

Slovenia

17. List of Promacta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7795293 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
May, 2023

(8 days ago)

US7160870

(Pediatric)

NOVARTIS Thrombopoietin mimetics
May, 2023

(9 days ago)

Do you want to check out PROMACTA patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 16, 2025

Drugs and Companies using ELTROMBOPAG OLAMINE ingredient

Market Authorisation Date: 20 November, 2008

Treatment: Patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy; Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic imm...

Dosage: TABLET;ORAL

How can I launch a generic of PROMACTA before it's patent expiration?
More Information on Dosage

PROMACTA family patents

8

United States

2

Japan

2

Korea, Republic of

2

European Union

1

Spain

1

Hong Kong

1

Austria

1

Malaysia

1

Iceland

1

Denmark

1

Poland

1

Germany

1

Russia

1

China

1

Brazil

1

Canada

1

Argentina

1

Norway

1

New Zealand

1

Cyprus

1

Israel

1

Portugal

1

Taiwan

1

Mexico

1

Australia

1

South Africa

1

Lithuania

1

Slovenia

18. List of Promacta Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7795293 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
May, 2023

(8 days ago)

US7160870

(Pediatric)

NOVARTIS Thrombopoietin mimetics
May, 2023

(9 days ago)

Do you want to check out PROMACTA KIT patents from before 2022?
Exclusivity Exclusivity Expiration
ODE* (ODE*) Nov 16, 2025

Drugs and Companies using ELTROMBOPAG OLAMINE ingredient

Market Authorisation Date: 24 August, 2015

Treatment: Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); Treatment of thrombocytopenia in patients with chronic hepatitis...

Dosage: FOR SUSPENSION;ORAL

How can I launch a generic of PROMACTA KIT before it's patent expiration?
More Information on Dosage

PROMACTA KIT family patents

8

United States

2

Japan

2

Korea, Republic of

2

European Union

1

Spain

1

Hong Kong

1

Austria

1

Malaysia

1

Iceland

1

Denmark

1

Poland

1

Germany

1

Russia

1

China

1

Brazil

1

Canada

1

Argentina

1

Norway

1

New Zealand

1

Cyprus

1

Israel

1

Portugal

1

Taiwan

1

Mexico

1

Australia

1

South Africa

1

Lithuania

1

Slovenia

19. List of Revlimid drug patents

REVLIMID's oppositions filed in EPO
Can you believe REVLIMID received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8648095 CELGENE Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor
May, 2023

(14 days ago)

US9101621 CELGENE Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
May, 2023

(14 days ago)

US8530498 CELGENE Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione
May, 2023

(14 days ago)

US9101622 CELGENE Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone
May, 2023

(14 days ago)

US9155730 CELGENE Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent
May, 2023

(14 days ago)

US9393238 CELGENE Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent
May, 2023

(14 days ago)

Do you want to check out REVLIMID patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 28, 2026

Drugs and Companies using LENALIDOMIDE ingredient

Market Authorisation Date: 27 December, 2005

Treatment: Use of revlimid (lenalidomide) for the treatment of patients with multiple myeloma, in combination with dexamethasone; Use of revlimid (lenalidomide) for the treatment of patients with multiple myelom...

Dosage: CAPSULE;ORAL

How can I launch a generic of REVLIMID before it's patent expiration?
More Information on Dosage

REVLIMID family patents

89

United States

27

Canada

26

China

24

European Union

23

Japan

13

New Zealand

13

Korea, Republic of

13

Australia

11

Mexico

9

Hong Kong

8

Israel

7

Spain

7

Denmark

7

Portugal

7

South Africa

6

Norway

6

Taiwan

5

Poland

5

Brazil

4

Cyprus

4

Costa Rica

4

Slovenia

3

Russia

3

Ukraine

3

Argentina

3

ME

3

Hungary

2

Austria

2

Iceland

2

RS

2

Peru

2

Ecuador

AP

1

AP

1

Germany

YU

1

Yugoslavia

1

Morocco

EA

1

EA

OA

1

OA

1

Croatia

1

Georgia

1

Luxembourg

20. List of Selzentry drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7368460

(Pediatric)

VIIV HLTHCARE Tropane derivatives useful in therapy
May, 2023

(4 days ago)

Do you want to check out SELZENTRY patents from before 2022?
Exclusivity Exclusivity Expiration
New Patient Population (NPP) Oct 30, 2023
Pediatric Exclusivity (PED) Apr 30, 2024

Drugs and Companies using MARAVIROC ingredient

Market Authorisation Date: 04 November, 2016

Treatment: NA

Dosage: SOLUTION;ORAL

How can I launch a generic of SELZENTRY before it's patent expiration?
More Information on Dosage

21. List of Stendra drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7501409 METUCHEN PHARMS Preparations for oral administration
May, 2023

(24 days ago)

Do you want to check out STENDRA patents from before 2022?
Exclusivity Exclusivity Expiration
M (M) Oct 18, 2025

Drugs and Companies using AVANAFIL ingredient

Market Authorisation Date: 27 April, 2012

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of STENDRA before it's patent expiration?
More Information on Dosage

STENDRA family patents

4

Japan

2

Australia

1

New Zealand

1

United States

1

Korea, Republic of

1

China

1

Spain

1

Hong Kong

1

Austria

1

Canada

1

Mexico

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in